

# Bone Medical

## **ASX/MEDIA RELEASE Share Issue**

**7 February 2012:** International biopharmaceutical company, Bone Medical Limited (ASX: BNE), wishes to advise that it has issued and allotted 17,500,000 fully paid ordinary shares (**Shares**) to La Jolla Cove Investors, Inc. following the conversion of A\$115,500 of a convertible note with a face value of US\$1,500,000 (pursuant to a convertible note facility of up to US\$6,000,000).

An Appendix 3B reflecting the revised capital structure following the issue of the Shares has been released with this announcement.

**- ENDS -**


**Enquiries:**

Dr Roger New  
Chairman  
Office: +44 207 794 1512

Peter Young  
CEO  
Mobile: +1 201 841 9681

Leon Ivory  
Director  
Mobile: +61 419 428 264

or visit: [www.bonemedical.com](http://www.bonemedical.com)



# Bone Medical

## About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical company focused on developing significant new products for the growing market in the treatment of bone disease, especially osteoporosis and arthritis. The Company's product pipeline includes:

- Phase II clinical-stage programs for the oral delivery of two well-established peptides which have historically been limited to nasal or injectable delivery
  - Capsitonin™ (oral calcitonin)
    - Osteoporosis
    - Osteoarthritis
  - CaPTHymone™ (oral parathyroid hormone) for osteoporosis
- Novel, potential breakthrough preclinical-stage compounds
  - BN006 – oral TNF-alpha inhibitor for rheumatoid arthritis (RA)
  - BN007 – collagen tolerance & joint protection agent for RA
  - BN005 & BN008 – bone cell regulation for osteoporosis

## About La Jolla Cove Investors, Inc.

Founded in 1995, La Jolla Cove Investors, Inc. has entered into more than US\$300 million in financing agreements with publicly traded companies. We seek to partner with businesses looking for capital and strategic advice to expand their current operations. Our expertise lies in creating flexible financial structures which enable a company to grow without impacting working capital needs.

### Enquiries:

Travis W Huff

Portfolio Manager

Ph: +1 (415) 409-3232

or visit: [www.ljcinvestors.com](http://www.ljcinvestors.com)

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Bone Medical Limited

ABN

70 009 109 755

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1 +Class of +securities issued or to be issued

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>					
<p>5 Issue price or consideration</p>					
<p>6 Purpose of the issue          (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>					
<p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p>					
<p>8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="686 1444 997 1489">Number</th> <th data-bbox="997 1444 1284 1489">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="686 1489 997 1702"></td> <td data-bbox="997 1489 1284 1702"></td> </tr> </tbody> </table>	Number	+Class		
Number	+Class				

---

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)		
10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		

## Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required?		
12 Is the issue renounceable or non-renounceable?		
13 Ratio in which the +securities will be offered		
14 +Class of +securities to which the offer relates		
15 +Record date to determine entitlements		
16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17 Policy for deciding entitlements in relation to fractions		
18 Names of countries in which the entity has +security holders who will not be sent new issue documents  <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>		
19 Closing date for receipt of acceptances or renunciations		

---

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

- |    |   |  |
|----|---|--|
| 20 | Names of any underwriters   |  |
| 21 | Amount of any underwriting fee or commission  |  |
| 22 | Names of any brokers to the issue   |  |
| 23 | Fee or commission payable to the broker to the issue  |  |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders   |  |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting  |  |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled  |  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders |  |
| 28 | Date rights trading will begin (if applicable)  |  |
| 29 | Date rights trading will end (if applicable)  |  |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker?   |  |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?  |  |

---

+ See chapter 19 for defined terms.

32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Despatch date

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional <sup>+</sup>securities

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

**Entities that have ticked box 34(b)**

38	Number of securities for which +quotation is sought	17,500,000					
39	Class of +securities for which quotation is sought	Fully Paid Ordinary shares					
40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?  If the additional securities do not rank equally, please state: <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	Yes					
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)	Conversion of AUD\$115,500 of convertible notes with a face value of US\$1,500,000 (pursuant of a convertible note facility of up to US\$6,000,000)					
42	Number and +class of all +securities quoted on ASX ( <i>including</i> the securities in clause 38)	<table border="1"> <thead> <tr> <th data-bbox="710 1471 1013 1514">Number</th> <th data-bbox="1013 1471 1300 1514">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="710 1514 1013 1700">166,050,872</td> <td data-bbox="1013 1514 1300 1700">Ordinary shares</td> </tr> </tbody> </table>	Number	+Class	166,050,872	Ordinary shares	
Number	+Class						
166,050,872	Ordinary shares						

---

+ See chapter 19 for defined terms.

**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
  
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  
  - There is no reason why those +securities should not be granted +quotation.
  
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
  
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
  
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Mark Clements  
Company Secretary  
7 February 2012

---

+ See chapter 19 for defined terms.